Anne E. Borgman, MD

Dr. Anne E. Borgman is an accomplished CMO, business executive, scientific advisor and board director with 20+ years of experience devising clinical development strategies and successfully leading teams to excellence and timely execution in oncology-hematology drug approvals. Dr. Borgman’s strength lies in her ability to organize and galvanize teams to fulfil mission critical business objectives. She is a creative problem solver and developer of human capital. Her broad network and depth of regulatory interactions and experience developing oncology and hematology drugs enables her to quickly synthesize the competitive landscape and forge a strategic path forward in a complex landscape collaboratively with key stakeholders. 

Dr. Borgman has led teams to successful approval of several oncology assets. Most recently while Therapeutic Area Head Hematology-Oncology and Vice President at Jazz Pharmaceuticals, she led a successful filing for a recombinant asparaginase using the intensive Real Time Oncology Review process, and expanded filings for other hematology-oncology assets. Prior, while Vice President at Exelixis, Inc. she led several successful filings for the lead asset cabozantinib, including a U.S. and European approval in renal cell carcinoma, a U.S. and European approval in hepatocellular carcinoma, and a European approval in medullary thyroid carcinoma. Additionally, Dr. Borgman led the filing for an accelerated approval for liposomal vincristine in adult relapsed acute lymphoblastic lymphoma while Chief Medical Officer at Hana Biosciences. Dr. Borgman created the early development strategies for the Bcl-2/Bcl-XL inhibitor (now venetoclax) and veliparib while Global Project Head for Abbott Laboratories. 

In addition to her strong core competency in hematology oncology drug development, she has led companies through growth phases at every stage in her career. Her ability to build strong partnerships across the healthcare sector, both internally and externally, has delivered proven results throughout her career, with patient benefit at the center. 

She serves on the Board of Directors of NextCure, Inc. a biotechnology company at the nexus of immunooncology and targeted therapies, Curis, targeted therapies for AML (Acute Myeloid Leukemia), and NiKang, a privately owned clinical stage biotech company focused on discovering and developing innovative small molecule oncology medicines. She is an active mentor and passionate about cancer treatment, as evidenced by her role on the advisory boards of Healthcare BusinessWomen’s Association (HBA), Y-ME national breast cancer association, Bear Necessities Pediatric Cancer Foundation, CureSearch For Children’s Cancers, and prior volunteer faculty positions in pediatric hematology oncology and stem cell transplant at both University of Chicago Comer Children’s Hospital and Lucile Packard Children’s Hospital Stanford. She uses her knowledge, energy and engaging style to facilitate awareness, connect and innovate. 

Dr. Borgman received an MD from Loyola University Chicago Stritch School of Medicine. She received a BS degree in Biochemistry from University of Illinois, Urbana-Champaign. Dr. Borgman completed a Residency in Pediatrics from Baylor College of Medicine in Houston, Texas, and a Fellowship in Pediatric Hematology-Oncology and Bone Marrow Transplantation from the David Geffen School of Medicine at UCLA. In addition, Dr. Borgman is a graduate of the Stanford Executive Program and an alumnus of Stanford University’s Graduate School of Business.